ENDE

Account

Overview · Filed: —

UPC_APP_24524/2025

NOVEL ANTITUMORAL USE OF CABAZITAXEL

Procedural & sub-applicationsCase Management OrdersMunich LDApplication Rop 333—

Overview Decisions Documents Timeline

Parties

Claimants

Sanofi SA(Sanofi Group)
Sanofi Winthrop Industrie(Sanofi Group)
Sanofi-Aventis GmbH(Sanofi Group)
Sanofi Belgium(Sanofi Group)
Sanofi-Aventis Deutschland GmbH(Sanofi Group)
Sanofi S.r.l.(Sanofi Group)
Sanofi B.V.(Sanofi Group)
Sanofi - Produtos Farmaceuticos Lda(Sanofi Group)
Sanofi AB(Sanofi Group)
Sanofi A/S(Sanofi Group)

Reps: Frédéric Chevallier (McDermott Will & Emery)

Respondents

Zentiva France
Zentiva Pharma GmbH
Zentiva, k.s.

Reps: Anja Lunze (Taylor Wessing); Elisabeth Greiner (df-mp)

Judges

Matthias ZigannPresiding Judge and Judge-Rapporteur
Alima ZanaLegally Qualified Judge
Tobias PichlmaierLegally Qualified Judge
Carola WagnerTechnically Qualified Judge

Patents

EP2493466

CPC codes: A61K38/193, A61K31/573, A61P35/04, A61K31/164, A61K31/56, A61P43/00, A61P13/08, A61P15/00, A61K31/337, A61P35/00, A61K45/06, A61P25/16

Sector: Pharmaceutical & Medical

Outcome

Procedural only

Filed: —

First decided: Jun 27, 2025

Language: —